ENTPD8

Summary

ENTPD8 (ectonucleoside triphosphate diphosphohydrolase 8, HGNC:24860) is a protein-coding gene on chromosome 9q34.3, encoding Ectonucleoside triphosphate diphosphohydrolase 8 (Q5MY95). Canalicular ectonucleoside NTPDase responsible for the main hepatic NTPDase activity.

Predicted to enable GDP phosphatase activity; UDP phosphatase activity; and ribonucleoside triphosphate phosphatase activity. Predicted to be involved in nucleoside diphosphate catabolic process. Predicted to act upstream of or within nucleoside diphosphate biosynthetic process and nucleoside monophosphate biosynthetic process. Predicted to be located in membrane. Predicted to be active in plasma membrane.

Source: NCBI Gene 377841 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 137 total
• Phenotypes (HPO): 1
• Druggable target: yes
• MANE Select transcript: NM_001033113

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24860
Approved symbol	ENTPD8
Name	ectonucleoside triphosphate diphosphohydrolase 8
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Aliases	UNQ2492, NTPDase-8
Ensembl gene	ENSG00000188833
Ensembl biotype	protein_coding
OMIM	616748
Entrez	377841

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 20 protein_coding, 1 retained_intron

ENST00000344119, ENST00000371506, ENST00000461823, ENST00000493135, ENST00000881602, ENST00000881603, ENST00000881604, ENST00000881605, ENST00000881606, ENST00000881607, ENST00000881608, ENST00000881609, ENST00000881610, ENST00000881611, ENST00000912767, ENST00000912768, ENST00000967090, ENST00000967091, ENST00000967092, ENST00000967093, ENST00000967094

RefSeq mRNA: 2 — MANE Select: NM_001033113 NM_001033113, NM_198585

CCDS: CCDS43913, CCDS7043

Canonical transcript exons

ENST00000371506 — 10 exons

Exon	Start	End
ENSE00001367641	137437159	137437309
ENSE00001383780	137436869	137437028
ENSE00001415542	137436521	137436751
ENSE00003504010	137438160	137438305
ENSE00003507784	137437967	137438084
ENSE00003532908	137435204	137435338
ENSE00003604729	137434364	137435105
ENSE00003630227	137436013	137436276
ENSE00003648783	137435719	137435829
ENSE00003898778	137441286	137441357

Expression profiles

Bgee: expression breadth broad, 90 present calls, max score 93.14.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.8751 / max 111.0288, expressed in 137 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103365	0.8039	137
103364	0.0711	52

Top tissues by expression

104 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	93.14	gold quality
duodenum	UBERON:0002114	90.28	gold quality
right lobe of liver	UBERON:0001114	82.25	gold quality
small intestine Peyer’s patch	UBERON:0003454	81.68	gold quality
transverse colon	UBERON:0001157	81.66	gold quality
small intestine	UBERON:0002108	81.00	gold quality
rectum	UBERON:0001052	79.39	gold quality
liver	UBERON:0002107	78.98	gold quality
pituitary gland	UBERON:0000007	73.42	gold quality
adenohypophysis	UBERON:0002196	71.60	gold quality
metanephros cortex	UBERON:0010533	70.64	gold quality
intestine	UBERON:0000160	70.41	gold quality
gall bladder	UBERON:0002110	70.10	gold quality
body of stomach	UBERON:0001161	68.46	gold quality
colon	UBERON:0001155	67.02	gold quality
adult mammalian kidney	UBERON:0000082	66.96	gold quality
stomach	UBERON:0000945	65.89	gold quality
body of pancreas	UBERON:0001150	64.73	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	64.10	gold quality
fundus of stomach	UBERON:0001160	63.23	gold quality
cortex of kidney	UBERON:0001225	63.00	gold quality
kidney	UBERON:0002113	62.75	gold quality
saliva-secreting gland	UBERON:0001044	62.68	gold quality
minor salivary gland	UBERON:0001830	61.74	gold quality
vermiform appendix	UBERON:0001154	59.47	gold quality
colonic epithelium	UBERON:0000397	58.36	silver quality
pancreas	UBERON:0001264	58.29	gold quality
right uterine tube	UBERON:0001302	57.85	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	56.86	gold quality
bone marrow cell	CL:0002092	55.75	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-8410	yes	12.68
E-CURD-114	yes	12.13
E-GEOD-125970	yes	7.07
E-ANND-3	yes	3.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

11 targeting ENTPD8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-3620-3P	97.78	64.88	772
HSA-MIR-6865-3P	97.54	64.67	684
HSA-MIR-3173-5P	97.35	65.82	1282
HSA-MIR-6799-3P	97.35	65.60	1302
HSA-MIR-6828-3P	96.06	67.61	1155
HSA-MIR-874-3P	95.02	65.66	806
HSA-MIR-6850-5P	94.72	64.25	62

Literature-anchored findings (GeneRIF, showing 1)

• NTPDase8 is the canalicular ecto-ATPase/ATPDase and is responsible for the main hepatic NTPDase activity. (PMID:17095758)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	entpd8	ENSDARG00000005565
mus_musculus	Entpd8	ENSMUSG00000036813
rattus_norvegicus	Entpd8	ENSRNOG00000009239

Paralogs (7): ENTPD2 (ENSG00000054179), ENTPD1 (ENSG00000138185), ENTPD3 (ENSG00000168032), ENTPD5 (ENSG00000187097), ENTPD4 (ENSG00000197217), ENTPD6 (ENSG00000197586), ENTPD7 (ENSG00000198018)

Protein

Protein identifiers

Ectonucleoside triphosphate diphosphohydrolase 8 — Q5MY95 (reviewed: Q5MY95)

All UniProt accessions (2): Q5MY95, H7C5J8

UniProt curated annotations — full annotation on UniProt →

Function. Canalicular ectonucleoside NTPDase responsible for the main hepatic NTPDase activity. Catalyzes the hydrolysis of nucleoside triphosphates (NTPs) and diphosphates (NDPs). The enzyme sequentially removes phosphate groups in two successive steps, converting NTPs to nucleoside monophosphates (NMPs) via NDP intermediates. This activity contributes to the regulation of extracellular levels of nucleotides. Hydrolyzes ATP, UTP, ADP, and UDP and prefers triphosphonucleosides and adenine over uracil as substrates. Does not hydrolyzes AMP.

Subcellular location. Cell membrane.

Post-translational modifications. N-glycosylated.

Activity regulation. Not inhibited by ARL 67156. ADP hydrolase activity is inhibited by high concentrations (5-10 mM) of azide with the greatest inhibition (80-90%) obtained at pH 6.4 using MgADP as the substrate. ATP hydrolase activity is inhibited by several detergents as well as benzyl alcohol.

Cofactor. Ca(2+) or Mg(2+). Has lower efficiency with Mg(2+).

Domain organisation. The transmembranous domains are involved in regulation of enzyme activity.

Similarity. Belongs to the GDA1/CD39 NTPase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5MY95-1	1	yes
Q5MY95-2	2

RefSeq proteins (2): NP_001028285, NP_940987 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000407	GDA1_CD39_NTPase	Family

Pfam: PF01150

Enzyme classification (BRENDA):

• EC 3.6.1.5 — apyrase (BRENDA: 66 organisms, 384 substrates, 230 inhibitors, 158 Km, 64 kcat entries)

Substrate kinetics (BRENDA)

29 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0025–8.7	44
ADP	0.0025–5.3	42
UDP	0.0113–0.555	7
GDP	0.0114–0.357	6
UTP	0.01–0.207	5
N-[5-[4-CARBOXY-3-(3-OXO-9,9A-DIHYDRO-3H-XANTHEN	0.0133–0.105	4
DATP	0.018–0.89	3
DCTP	0.029–0.276	3
DGTP	0.028–0.16	3
IDP	0.0105–0.622	3
1,N6-ETHENO-ADP	0.073–0.114	2
1,N6-ETHENO-ATP	0.024–0.031	2
2’(3’)-O-(2,4,6-TRINITROPHENYL)ADENOSINE 5’-DIPH	0.009–0.019	2
2’(3’)-O-(2,4,6-TRINITROPHENYL)ADENOSINE 5’-TRIP	0.008–0.018	2
3’(2’)-O-(METHYLANTHRANOYL)ADENOSINE 5’-DIPHOSPH	0.014–0.017	2

Catalyzed reactions (Rhea), 9 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)
• ATP + 2 H2O = AMP + 2 phosphate + 2 H(+) (RHEA:20988)
• a ribonucleoside 5’-triphosphate + H2O = a ribonucleoside 5’-diphosphate + phosphate + H(+) (RHEA:23680)
• a ribonucleoside 5’-triphosphate + 2 H2O = a ribonucleoside 5’-phosphate + 2 phosphate + 2 H(+) (RHEA:36795)
• a ribonucleoside 5’-diphosphate + H2O = a ribonucleoside 5’-phosphate + phosphate + H(+) (RHEA:36799)
• ADP + H2O = AMP + phosphate + H(+) (RHEA:61436)
• UDP + H2O = UMP + phosphate + H(+) (RHEA:64876)
• UTP + 2 H2O = UMP + 2 phosphate + 2 H(+) (RHEA:64896)
• UTP + H2O = UDP + phosphate + H(+) (RHEA:64900)

UniProt features (17 total): disulfide bond 4, topological domain 3, glycosylation site 3, sequence variant 2, transmembrane region 2, chain 1, splice variant 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5MY95-F1	94.41	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 168 (proton acceptor)

Disulfide bonds (4): 78–102, 246–292, 329–335, 381–403

Glycosylation sites (3): 67, 304, 363

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8850843	Phosphate bond hydrolysis by NTPDase proteins

MSigDB gene sets: 49 (showing top): GOBP_NUCLEOSIDE_DIPHOSPHATE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_TRIPHOSPHATE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_CATABOLIC_PROCESS, GOBP_NUCLEOSIDE_MONOPHOSPHATE_BIOSYNTHETIC_PROCESS, KEGG_PURINE_METABOLISM, GOBP_NUCLEOSIDE_PHOSPHATE_CATABOLIC_PROCESS, GOBP_NUCLEOSIDE_TRIPHOSPHATE_CATABOLIC_PROCESS, GOBP_NUCLEOSIDE_MONOPHOSPHATE_METABOLIC_PROCESS, SCGGAAGY_ELK1_02, GOMF_NUCLEOSIDE_DIPHOSPHATE_PHOSPHATASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES

GO Biological Process (5): nucleoside monophosphate biosynthetic process (GO:0009124), nucleoside diphosphate biosynthetic process (GO:0009133), nucleoside diphosphate catabolic process (GO:0009134), ribonucleoside diphosphate catabolic process (GO:0009191), ribonucleoside triphosphate catabolic process (GO:0009203)

GO Molecular Function (10): apyrase activity (GO:0004050), GDP phosphatase activity (GO:0004382), ATP binding (GO:0005524), ribonucleoside triphosphate phosphatase activity (GO:0017111), UDP phosphatase activity (GO:0045134), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787), nucleoside diphosphate phosphatase activity (GO:0017110)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Nucleotide catabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
pyrophosphatase activity	3
nucleoside phosphate biosynthetic process	2
nucleoside diphosphate metabolic process	2
nucleoside diphosphate phosphatase activity	2
nucleoside monophosphate metabolic process	1
nucleoside phosphate catabolic process	1
nucleoside diphosphate catabolic process	1
ribonucleoside diphosphate metabolic process	1
nucleoside triphosphate catabolic process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1030 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ENTPD8	ITGA2B	P08514	727
ENTPD8	P2RY2	P41231	719
ENTPD8	PAPSS1	O43252	702
ENTPD8	PANX1	Q96RD7	692
ENTPD8	P2RY1	P47900	686
ENTPD8	PAPSS2	O95340	666
ENTPD8	P2RY12	Q9H244	665
ENTPD8	P2RX1	P51575	654
ENTPD8	GP6	Q9HCN6	623
ENTPD8	P2RY6	Q15077	610
ENTPD8	P2RY11	Q96G91	609
ENTPD8	ADA	P00813	594
ENTPD8	P2RX7	Q99572	591
ENTPD8	SELP	P16109	584
ENTPD8	P2RY4	P51582	583

IntAct

1 interactions, top by confidence:

BioGRID (4): ENTPD8 (Two-hybrid), ENTPD8 (Negative Genetic), ENTPD8 (Positive Genetic), ENTPD8 (Negative Genetic)

ESM2 similar proteins: A0JND9, E1BPW0, O14773, O18956, O35795, O55026, O75173, O75355, O75356, O75578, O89023, O93295, P08514, P08648, P11688, P17405, P49961, P55772, P56201, P79784, P97687, Q04519, Q0VD19, Q12794, Q32M88, Q49HH9, Q49KI5, Q5DRK1, Q5IS74, Q5MY95, Q5RFL1, Q5RFQ8, Q60HH1, Q6P3E7, Q6P6S9, Q717C1, Q717C2, Q7RTX0, Q8BFW6, Q8BNJ2

Diamond homologs: A0JND9, D2GZV9, O18956, O35795, O55026, O75354, O75355, O75356, O93295, P49961, P55772, P79784, P97687, Q3U0P5, Q5DRK1, Q5MY95, Q6NQA8, Q6P6S9, Q8BFW6, Q8H1D8, Q8H7L6, Q8K0L2, Q9ER31, Q9MYU4, Q9QYC8, Q9SQG2, Q9WUZ9, Q9XU84, Q9Y5L3, Q9XI62, E1BPW0, P32621, Q9HEM6, Q9USP2, Q6Z4P2, E1C1L6, O80612, Q9SPM5, P52914, P80595

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

137 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	112
Likely benign	12
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1854 predictions. Top by Δscore:

Variant	Effect	Δscore
9:137435199:GTCAC:G	donor_loss	1.0000
9:137435200:TCA:T	donor_loss	1.0000
9:137435201:CACC:C	donor_loss	1.0000
9:137435203:C:G	donor_loss	1.0000
9:137435203:CCTG:C	donor_gain	1.0000
9:137435347:C:CT	acceptor_gain	1.0000
9:137435347:C:T	acceptor_gain	1.0000
9:137435348:A:T	acceptor_gain	1.0000
9:137435745:C:CA	donor_gain	1.0000
9:137436011:A:AC	donor_gain	1.0000
9:137436012:C:CC	donor_gain	1.0000
9:137436518:GACCT:G	donor_loss	1.0000
9:137436520:C:A	donor_loss	1.0000
9:137436550:G:C	donor_gain	1.0000
9:137436747:GAGTA:G	acceptor_gain	1.0000
9:137436748:AGTA:A	acceptor_gain	1.0000
9:137436749:GTA:G	acceptor_gain	1.0000
9:137436750:TA:T	acceptor_gain	1.0000
9:137436752:C:CA	acceptor_loss	1.0000
9:137436752:C:CC	acceptor_gain	1.0000
9:137436753:T:G	acceptor_loss	1.0000
9:137438085:C:CC	acceptor_gain	1.0000
9:137441280:CCTCA:C	donor_loss	1.0000
9:137441281:CTCA:C	donor_loss	1.0000
9:137441282:TCAC:T	donor_loss	1.0000
9:137441283:CACC:C	donor_loss	1.0000
9:137441284:A:AG	donor_loss	1.0000
9:137441285:C:CA	donor_loss	1.0000
9:137441305:C:A	donor_gain	1.0000
9:137435101:CCCGC:C	acceptor_gain	0.9900

AlphaMissense

3183 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:137435738:C:T	C381Y	0.989
9:137436662:G:C	F215L	0.988
9:137436662:G:T	F215L	0.988
9:137436664:A:G	F215L	0.988
9:137435213:G:C	F429L	0.987
9:137435213:G:T	F429L	0.987
9:137435215:A:G	F429L	0.987
9:137436907:A:G	W173R	0.987
9:137436907:A:T	W173R	0.987
9:137435737:G:C	C381W	0.986
9:137435738:C:G	C381S	0.985
9:137435739:A:T	C381S	0.985
9:137435084:A:G	W440R	0.984
9:137435084:A:T	W440R	0.984
9:137435739:A:G	C381R	0.984
9:137436115:G:C	C316W	0.984
9:137436905:C:A	W173C	0.984
9:137436905:C:G	W173C	0.984
9:137436244:G:C	C273W	0.983
9:137436245:C:G	C273S	0.983
9:137436246:A:T	C273S	0.983
9:137435082:C:A	W440C	0.982
9:137435082:C:G	W440C	0.982
9:137435228:C:A	W424C	0.982
9:137435228:C:G	W424C	0.982
9:137435291:A:C	C403W	0.982
9:137435292:C:T	C403Y	0.982
9:137436116:C:T	C316Y	0.982
9:137436245:C:T	C273Y	0.982
9:137436578:G:C	S243R	0.981

dbSNP variants (sampled 300 via entrez): RS1000188152 (9:137438540 T>C), RS1000212286 (9:137437619 C>G), RS1000215814 (9:137441844 C>G,T), RS1000306736 (9:137434545 C>T), RS1000425176 (9:137434695 A>C), RS1000471911 (9:137438455 G>A), RS1000513533 (9:137436788 AC>A), RS1001496747 (9:137442034 T>C), RS1001718315 (9:137442089 G>A,C), RS1001780401 (9:137442348 C>T), RS1002274306 (9:137436291 G>A,T), RS1002759574 (9:137441443 C>T), RS1002805472 (9:137435534 G>A), RS1003050562 (9:137439956 C>G,T), RS1003115638 (9:137439601 T>G)

Disease associations

OMIM: gene MIM:616748 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): microcephaly (MONDO:0001149)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5338 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
dicrotophos	decreases expression	1
methyleugenol	decreases expression	1
bisphenol A	decreases methylation	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression	1
perfluorooctanoic acid	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
Rosiglitazone	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Glyphosate	affects methylation	1
Cadmium	decreases expression	1
Calcitriol	increases expression, affects cotreatment	1
Estradiol	affects cotreatment, decreases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Sarin	decreases expression	1
Testosterone	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1

ChEMBL screening assays

21 unique, capped per target: 17 binding, 4 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1002519	Binding	Activity of human NTPDase 8 expressed in human 293T cells assessed as drug hydrolysis at 100 uM after 20 mins relative to ATP	Identification of hydrolytically stable and selective P2Y(1) receptor agonists. — Eur J Med Chem
CHEMBL2390587	ADMET	Drug metabolism assessed as human nucleotide triphosphate diphosphohydrolase8-mediated compound hydrolysis at 4.24 mM after 1 hr by HPLC analysis relative to ADP	Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. — J Med Chem

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05518188	PHASE1/PHASE2	RECRUITING	Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT00001639	Not specified	COMPLETED	Evaluation of Patients With Unresolved Chromosome Abnormalities
NCT01151462	Not specified	WITHDRAWN	Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
NCT01565005	Not specified	COMPLETED	Microcephaly Genetic Deficiency in Neural Progenitors
NCT02510170	Not specified	COMPLETED	Fetal and Maternal Head Circumference During Pregnancy in Israeli Population
NCT02741882	Not specified	COMPLETED	Zika and Microcephaly: Case-control Study
NCT02943304	Not specified	COMPLETED	Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
NCT03255369	Not specified	UNKNOWN	Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT03325946	Not specified	RECRUITING	The FBRI VTC Neuromotor Research Clinic
NCT03330600	Not specified	COMPLETED	Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
NCT03548779	Not specified	COMPLETED	North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
NCT03651687	Not specified	COMPLETED	Guangzhou Surveillance and Clinical Study in Microcephaly (GSCSM)
NCT03922594	Not specified	TERMINATED	Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
NCT04816175	Not specified	COMPLETED	Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay
NCT05322980	Not specified	COMPLETED	Summary of Infants Weighing 500 Grams or Less
NCT06019182	Not specified	RECRUITING	MEHMO Natural History and Biomarkers
NCT06566066	Not specified	RECRUITING	Register for Patients With Thyroid Hormone Resistance.